Can an Iron Infusion Harm an Unborn Baby?

Current evidence from multiple randomized trials and systematic reviews indicates that iron infusions given during the second or third trimester of pregnancy do not appear to harm the unborn baby. Rates of preterm birth, stillbirth, and neonatal death are similar whether a pregnant person receives iron intravenously or by mouth. That said, there are nuances worth understanding, including why the first trimester is treated differently, what rare maternal reactions can mean for the fetus, and why the formulation of iron matters.

Why Some Pregnant Women Need Iron Infusions

Iron deficiency anemia is one of the most common complications of pregnancy worldwide. As blood volume expands and the fetus draws on the mother’s iron stores, many women find that diet and even oral iron supplements cannot keep up. Oral iron tablets are the standard first-line treatment, but they come with well-known gastrointestinal side effects like nausea, constipation, and cramping, which lead many women to stop taking them. For those who cannot tolerate oral iron, who do not absorb it well, or who have severe anemia, intravenous iron becomes the practical alternative.¹

The American College of Obstetricians and Gynecologists (ACOG) recommends confirming iron deficiency with lab work when anemia is found during pregnancy but notes that presumptive treatment is common in practice.² The optimal route of iron repletion remains an open question, which is part of why so many trials have compared IV and oral iron head to head in recent years.

Why the First Trimester Is Off-Limits

One of the clearest safety boundaries in this area is timing. Oral iron is the only option considered safe during the first trimester, because there is essentially no safety data on IV iron during the earliest weeks of pregnancy, when organ formation is happening most rapidly. IV iron is reserved for the second and third trimesters.³ This is not because anyone has demonstrated harm in the first trimester; it is because no one has studied it enough to rule harm out. The absence of data during organogenesis makes clinicians cautious, and for good reason. If you are in your first trimester and severely anemic, your provider will almost certainly manage it with oral supplements and close monitoring rather than an infusion.

What Large Studies Show About Fetal Safety

The strongest reassurance comes from systematic reviews that pool data from thousands of pregnancies. A recent meta-analysis covering seven studies and over 8,400 pregnancies found that the risk of preterm birth was essentially the same whether women received IV iron or oral iron. The preterm birth rate was about 13% in the IV iron group and 15% in the oral group, a difference that was not statistically meaningful. The same review found low to moderate certainty evidence that IV iron did not improve or worsen clearly objective neonatal outcomes including stillbirths and neonatal mortality.⁴

Another large meta-analysis found no difference in birth weight, gestational age at delivery, neonatal hemoglobin levels, or cesarean delivery rates between IV and oral iron groups. The one measurable difference was that babies in the IV iron group had higher ferritin levels at birth, suggesting better iron stores, though what that means for long-term health is still being studied.⁵ In practical terms, the babies whose mothers got IV iron were born at the same weight, the same gestational age, and with similar blood counts as those whose mothers took pills.

Rare Allergic Reactions and What They Mean for the Fetus

The risk that worries clinicians most is not a direct toxic effect on the baby but an acute allergic reaction in the mother. Modern IV iron formulations carry a very low rate of serious allergic events, estimated at fewer than 100 per million infusions for some preparations.¹ But rare does not mean impossible. A published case report documented an intrauterine death following a severe allergic reaction to iron sucrose that caused widespread swelling in the mother. The authors framed the case as a warning that even formulations generally considered safe can, in extremely rare circumstances, lead to fatal fetal outcomes through a severe maternal reaction.⁶

It is worth keeping perspective here. The case is notable precisely because it is unusual. Allergic reactions of that severity are exceedingly rare with current iron preparations, and infusions are given in clinical settings where the mother can be monitored and treated immediately. A Cochrane review comparing IV and oral iron in pregnancy found that IV iron likely does not increase the rate of severe maternal infections either.⁷ The overall safety profile, across thousands of patients in controlled trials, is reassuring. But the case report is a useful reminder that iron infusions are medical procedures, not entirely without risk, and that monitoring during and after infusion matters.

Side Effects That Have Actually Been Documented

Across clinical trials comparing the two most commonly used IV iron formulations in pregnancy, ferric carboxymaltose and iron sucrose, the side effects reported are mostly mild and short-lived. In one comparative study, mild adverse events occurred in about 8% of women receiving ferric carboxymaltose and about 11% receiving iron sucrose.⁸ Another randomized trial found no serious adverse events in either group. The most common issues were injection-site reactions and occasional mild stomach pain that resolved on its own. One patient in the ferric carboxymaltose group had temporarily elevated liver enzymes at three weeks, which returned to normal by six weeks.⁹

These are maternal side effects, not fetal ones. None of the trials reported adverse effects directly attributable to the baby. The distinction matters: the question of whether an iron infusion can harm the fetus is different from whether the mother might feel lousy for a few hours afterward. The latter happens occasionally; the former has not been demonstrated in any controlled study.

The Phosphate Question

One concern that has emerged in recent years, mostly with ferric carboxymaltose, is the potential for low phosphate levels in the mother, a condition called hypophosphatemia. Low phosphate sounds obscure, but severe cases can cause muscle weakness, bone pain, and in theory could affect fetal mineral metabolism. A study examining cord blood in babies born to mothers who received IV iron found no meaningful difference in phosphate or calcium levels compared to babies whose mothers took oral iron. The IV iron group had a cord blood phosphate level of 1.7 mmol/L versus 1.71 mmol/L in the oral group, and calcium levels were similarly indistinguishable.¹⁰

A systematic review looking specifically at hypophosphatemia as an adverse event in pregnant women receiving IV iron found the data frustratingly thin. Most studies did not report phosphate levels at all. One trial recorded reduced phosphate in a small number of patients given ferric carboxymaltose, but the investigators considered the drops clinically irrelevant. Because low phosphate is usually symptomless, and when symptoms do appear they overlap with general pregnancy complaints, the review concluded that the true incidence is essentially unknown.¹¹ This is an area where the evidence is genuinely incomplete rather than reassuring, and it is worth asking your provider about if you are offered ferric carboxymaltose specifically.

Oxidative Stress From IV Iron

Iron is a double-edged nutrient. The body needs it, but free iron can generate reactive molecules that damage cells. One concern about giving a large dose of iron all at once, rather than small amounts by mouth, is whether this spike could increase oxidative stress in the mother or the fetus. A study measuring markers of oxidative stress before and after IV iron sucrose in pregnant women found that one marker (malondialdehyde, a sign of cellular damage from reactive molecules) did increase after treatment. However, the body’s own antioxidant defenses, measured by several different enzymes and compounds, did not change meaningfully.¹²

The practical significance of a temporary bump in one oxidative marker, without corresponding depletion of antioxidant defenses, is unclear. The body appears to handle the iron load without a cascading stress response. Researchers continue to study this, but no trial has linked transient oxidative changes from IV iron to any measurable harm in the baby.

How the Placenta Manages Iron Delivery

The placenta is not a passive filter. It actively regulates how much iron reaches the fetus, and this built-in gatekeeping function is part of why large doses of IV iron given to the mother do not flood the baby with excess iron. The placenta takes up iron from the mother’s blood, processes it through its own cells, and releases a controlled amount into fetal circulation. Disruptions to this transport system can lead to problems, but the system is designed to buffer the fetus from fluctuations in the mother’s iron levels.¹³

This helps explain why studies consistently find that babies born to mothers who received IV iron have similar blood counts and birth weights to those whose mothers took oral iron, even though IV iron delivers the dose much faster and achieves higher maternal iron levels more quickly. The placenta adjusts what it transfers. The one measurable difference, as noted earlier, is that babies in IV iron groups tend to have somewhat higher ferritin at birth, which suggests slightly better iron stores but not an overload.

What Happens to the Baby After Birth

Beyond birth weight and immediate lab values, researchers have started looking at whether prenatal IV iron affects how children grow in the first year of life. A secondary analysis of a randomized trial compared growth measures at 12 months between children whose mothers received ferric carboxymaltose during pregnancy and those whose mothers received standard oral iron care. There was no difference in length, weight, or weight-for-length at any time point. Rates of stunting, underweight, and wasting were the same in both groups.¹⁴

This is reassuring but also highlights a limitation of the current evidence: most follow-up data only extends to the first year or so. Whether prenatal IV iron has any effect on long-term neurodevelopment, immune function, or iron status later in childhood is largely uncharted territory. The absence of harm at 12 months is encouraging, but the honest answer is that researchers have not tracked these children far enough to make definitive statements about effects that might emerge later.

What Happens When Severe Anemia Goes Untreated

Any discussion of whether IV iron could harm the baby needs to be weighed against what untreated severe anemia does to the baby. Severe maternal anemia is not a benign condition. Research using Doppler ultrasound has shown that fetuses of severely anemic mothers have altered blood flow patterns in the brain and umbilical cord, a compensatory response where the fetal body redirects blood to protect the brain at the expense of other organs. After the mother’s anemia was treated, these abnormal flow patterns returned to normal.¹⁵

Untreated iron deficiency anemia in pregnancy is associated with increased risks of preterm birth, low birth weight, and other complications. The relevant comparison is not “IV iron versus a perfectly healthy pregnancy” but “IV iron versus ongoing anemia that the mother cannot correct with pills.” For women with moderate to severe anemia who are not responding to oral supplements, the risks of leaving the anemia untreated are generally considered to outweigh the small risks of the infusion itself.

Why Your Provider Might Still Hesitate

Despite the reassuring trial data, you may encounter providers who are cautious about ordering IV iron during pregnancy. Part of this comes down to guidelines that have not fully caught up with the evidence. ACOG, for instance, acknowledges the benefits of treating iron deficiency anemia during pregnancy but describes the optimal route of iron repletion as uncertain.² Some clinicians interpret this conservatively, reserving IV iron for the most severe cases. Others are more liberal, especially for women in the third trimester who have not responded to weeks of oral supplementation and are approaching delivery still significantly anemic.

The cost and logistics of infusions also play a role. An iron infusion requires a clinical setting, monitoring time, and often insurance preauthorization, while a bottle of iron pills costs a few dollars. In resource-limited settings, this practical barrier can be decisive even when the clinical picture calls for IV treatment. If you believe you need IV iron and your provider seems reluctant, it is reasonable to ask what their specific concern is. Often the hesitation is not about fetal safety but about navigating an authorization process or a preference for exhausting oral options first.

Infection Risk and Iron

A question that occasionally surfaces in online forums is whether giving iron intravenously could increase the risk of infection in the mother or baby, since bacteria need iron to grow. A review examining the relationship between iron status and infection risk during pregnancy found that the relevant studies simply have not measured this carefully enough to draw conclusions. The data are lacking, not negative.¹⁶ A large Cochrane review, however, found that IV iron likely does not increase the rate of severe maternal infections compared to oral iron, which provides some indirect reassurance.⁷ The theoretical concern about feeding bacteria has not translated into a clinical problem in the trials conducted so far.

Choosing Between Iron Formulations

Not all IV iron products are the same, and the choice of formulation can matter. The most commonly used preparations in pregnancy are ferric carboxymaltose, iron sucrose, ferric isomaltose (also called iron isomaltoside), and low-molecular-weight iron dextran. Ferric carboxymaltose allows a large dose in a single short infusion, which is convenient, but it is the formulation most associated with the phosphate-lowering effect discussed earlier. Iron sucrose has a long safety record in pregnancy but typically requires multiple smaller infusions. Low-molecular-weight iron dextran can also be given as a single large dose and has a very low rate of serious reactions.¹

Head-to-head comparisons in pregnancy have generally found similar safety profiles. In one trial comparing ferric carboxymaltose and iron sucrose, adverse events were mild in both groups, though ferric carboxymaltose produced a larger rise in hemoglobin.⁸ The best formulation for a given patient depends on how severe the anemia is, how far along the pregnancy is, and what is available at the treatment facility. None of these formulations has been shown to be harmful to the fetus when used according to established protocols in the second or third trimester.

1
PubMed. Safety and efficacy of rapid (1,000 mg in 1 hr) intravenous iron dextran for treatment of maternal iron deficient anemia of pregnancy
2
PubMed Central. Identifying and treating iron deficiency anemia in pregnancy
3
PubMed Central. The Incidence, Complications and Treatment of Iron Deficiency in Pregnancy
4
PubMed Central. The effect of intravenous iron supplementation compared to oral iron supplementation during pregnancy on neonatal outcomes—a systematic review of randomized controlled trials
5
JAMA Network Open. Intravenous vs Oral Iron for Treating Iron Deficiency Anemia in Pregnancy: A Systematic Review and Meta-Analysis
6
PubMed Central. A rare occurrence of intrauterine death following an allergic reaction to iron sucrose
7
Cochrane Database of Systematic Reviews. Intravenous versus oral iron for treating iron deficiency anaemia in pregnancy
8
PubMed. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose
9
PubMed Central. Comparison of ferric Carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy- randomised controlled trial
10
PubMed. Newborn phosphocalcic metabolism after intravenous iron administration during pregnancy
11
PubMed Central. Incidence of adverse events in iron‐deficient pregnant women and surgical patients undergoing intravenous iron treatment with ferric isomaltose or ferric carboxymaltose: A systematic review
12
PubMed Central. Studying the Intravenous Iron Sucrose in Antioxidant Status and Oxidative Stress in Pregnant Females with Iron Deficiency Anemia
13
PubMed Central. Placental iron transport: The mechanism and regulatory circuits
14
JAMA Network Open. Prenatal Intravenous Iron and Child Growth: A Secondary Analysis of a Randomized Clinical Trial
15
PubMed Central. Fetal vascular adaptation before and after treatment of severe maternal anemia in pregnancy
16
PubMed Central. Influence of iron status on risk of maternal or neonatal infection and on neonatal mortality with an emphasis on developing countries